Review of the use of topotecan in ovarian carcinoma

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 11, 2004, Pages 2333-2340

  Ahmad, Tanya ^a   Gore, Martin ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Carcinoma; Chemotherapy; Ovarian review; Topotecan

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; GLYCOPROTEIN P INHIBITOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN; TREOSULFAN; VINCRISTINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CROSS REACTIVITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; INFECTIOUS COMPLICATION; MAXIMUM TOLERATED DOSE; MYALGIA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; FEMALE; HUMANS; OVARIAN NEOPLASMS; TOPOTECAN;

EID: 8544233543     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.11.2333     Document Type: Article

References (48)

1. FORBES C, SHIRRAN L, BAGNALL A-M et al.: A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. Health Technol. Assess. (2001) 5: o 28.
2. OZOLS RF, SCHWARTZ PE, EIFEL PJ: Ovarian Cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: Cancer. Principles and Practice of Oncology (6th edn). De Vita Jr VT, Hellman S, Rosenberg SA (Eds), Lippincott Williams and Wilkins, Philadelphia, USA (2001) 2: 597-1632.
3. OZOLS RF: Update of the NCCN ovarian cancer practice guidelines. Oncology (Hunting) (1997) 11:95-105.
4. WALL ME, WANI MC, COOK CE, PALMER KH: Plant antitumour agents: the isolation and structure of camptothecin, a novel alkaloidal leukaemia and tumour inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. (1996) 88:3888-3890.
5. MOERTEL CG, SCHUTT AJ, REITEMEIER RJ, HAHN RG: Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. (1972) 56: 5-101.
6. HSIANG YH, HERTZBERG R, HECHT S, LIU LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. (1985) 260:14873-14878.
7. HUSAIN I, MOHLER JL, SEIGLER HF, BESTERMAN JM: Elevation of topoisomerase I messenger RNA, protein and catalytic activity in human tumours: demonstration of tumour-type specificity and implications for cancer chemotherapy. Cancer Res. (1994) 54:539-546.
8. KINGSBURY WD, BOEHM JC, JAKAS DR et al.: Synthesis of water-soluble captothecin analogues: inhibition of topoisomerase I and antitumour activity. J. Med. Chem. (1991) 34:98-107.
9. HOUGHTON PJ, CHESHIRE PJ, MYERS L, STEWART CF, SYNOLD TW, HOUGHTON JA: Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumours. Cancer Chemother. Pharmacol. (1992) 31:229-239.
10. VERWEIJ J, LUND B, BEIJNEN J et al.: Phase I and pharmacokinetic study of topotecan, a new topoisomerase I inhibitor. Ann. Oncol. (1993) 4:673-678.
11. SALTZ L, SIROTT M, YOUNG et al.: Phase I dinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumours, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J. Natl. Cancer Inst. (1993) 85:1499-1507.
12. CREEMERS GJ, BOLIS G, GORE M et al.: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European Phase II srudy. J. Clin. Oncol. (1996) 14:3056-3061.
13. BOOKMAN MA, MALMSTROM H, BOLIS G et al.: Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label Phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol. (1998) 16:3345-3352.
14. MCGUIRE WP, BLESSING JA, BOOKMAN MA, LENTZ SS, DUNTON CJ: Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynaecologic Oncology Group study. J. Clin. Oncol. (2000) 18: 062-1067.
15. CESANO A, LANE SR, POULIN R, ROSS G, FIELD S SZ: Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int. J. Oncol. (1999) 15:1233-1238.
16. SWISHER EM, MUTCH DG, RADER JS, ELBENDARY A, HERZOG TJ: Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol. Oncol. (1997) 66:480-486.
17. KUDELKAAP, TRESUKOSOL D, EDWARDS CL et al.: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J. Clin. Oncol. (1996) 14: 552-1557.
18. RODRIGUEZ M, ROSE PG: Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol. Oncol. (2001) 83:257-262.
19. HOSKINS P, EISENHAUER E, BEARE S et al.: Randomised Phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study. J Clin. Oncol. (1998) 16: 233-2237.
20. MALIK IA: An open label evaluation of topotecan in patients with relapsed or refractory epithelial ovarian cancer - single institution experience in a developing country. Int. J. Gynecol. Cancer (2000) 10:443-448.
21. TEN BOKKEL HUININK W, GORE M, CARMICHAEL J et al.: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. (1997) 15:2183-2193.
22. TEN BOKKEL HUININK W, GORE M, CARMICHAEL J et al.: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Classic Papers Curr. Comments (2002) 7: 33-143.
23. GORE M, TEN BOKKEL HUININK W, CARMICHAEL J et al.: Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J. Clin. Oncol. (2001) 19: 1893-1900.
24. GORDON AN, FLEAGLE JT, GUTHRIE D, PARKIN DE, GORE ME, LANCAVE AJ: Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. (2002) 19:3312-3322.
25. MEIER W, DUBOIS A, KUHN W, PFISTERER J, KIMMING R, OLBRICHT S, RICHTER B: Topotecan versus treosulfan in recurrent ovarian cancer after initial therapy with platinum and paclitaxel. A prospective randomised Phase III study. Proc. Am. Soc. Clin. Oncol. (2003) 22:A1810.
26. VERMORKEN JB, GORE M, PERREN T et al.: Multicenter randomized Phase II study of oxaliplatin or topotecan in platinum-pretreated epithelial ovarian cancer patients. Proc. Am. Soc. Clin. Oncol. (2001) 20:A847.
27. BAHADORI HR, GREEN MR, CATAPANO CV: Synergistic interaction between topotecan and microtubule-interfering agents. Cancer Chemother. Pharmacol. (2001) 48:188-196.
28. MA J, MALIEPAARD M, NOOTER K et al.: Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother. Pharmacol. (1998) 41:307-316.
29. ROWINSKY EK, KAUFMANN SH, BAKER SD et al.: Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence. J. Clin. Oncol. (1996) 14 12):3053-3055.
30. SPEYER J, HOCHSTER H, WADLER S et al.: Effective first line therapy of ovarian cancer (OC) with cisplatin and prolonged topotecan infusion - A NYGOG/ECOG Study. Proc. Am. Soc. Clin. Oncol. (2000) 19:380a.
31. ESTAPE RE, ANGIOLI R, MENDEZ L et al.: 3-day topotecan and carboplatin in first line treatment of ovarian cancer: a Phase II trial. Proc. Am. Soc. Clin. Oncol. (2001) 20:219a.
32. CHOU TC, MOTZER RJ, TONG Y et al.: Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst. (1994) 86 20):1517-1524.
33. FRASCI G, PANZA N, COMELLA P et al.: Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study. Ann. Oncol. (1999) 10:355-358.
34. ARMSTRONG DK, O'REILLY S, BOOKMAN M et al.: Phase I study of topotecan (T), cisplatin (C), and paclitaxel (P) in newly diagnosed epithelial ovarian cancer, a Gynecologic Oncology Group (GOG 9602) study. Proc. Am. Soc. Clin. Oncol. (1998) 17:A350.
35. HERBEN VMM, NANNAN PANDAY VR, RICHEL DJ et al.: Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. J. Clin. Oncol. (1999) 17:747-755.
36. GONZALEZ-BECA R, ARRANZ JA, BORREGA P et al.: Weekly paclitaxel and carboplatin followed by topotecan as first-line therapy for patients with advanced epithelial ovarian cancer suboptimally debulked. Preliminary results. Proc. Am. Soc. Clin. Oncol. (2001) 20:A215.
37. HOSKINS P, EISENHOUER E, VERGOTE I et al.: Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J. Clin. Oncol. (2000) 18:4038-4044.
38. COPELAND LJ, BOOKMAN M, TRIMBLE E et al.: Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol. Oncol. (2003) 90(2 Pt. 2):S1-S7.
39. O'REILLY S, ROWINSKY EK, SLICHENMYER W et al.: Phase I and pharmacologic study of topotecan in patients with impaired renal function. J. Clin. Oncol. (1996) 14:3062-3073.
40. ARAVANTINOS G, ZAFIROPOULOS A, BAFALOUKOS D et al.: Topotecan in heavily pretreated platinum resistant ovarian cancer patients. 10th Symposium of New Drugs in Cancer Therapy, Amsterdam, The Netherlands (1998):67.
41. HOCHSTER H, WADLER S, RUNOWICZ C et al.: Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J. Clin. Oncol. (1999) 17 8):2553-2561.
42. GORE M, RUSTIN G, SCHULLER J et al.: Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer. Br. J. Cancer (2001) 84(8):1043-1046.
43. MARKMAN M, KENNEDY A, WEBSTER K et al.: Phase II evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol. Oncol. (2000) 79(1):116-119.
44. BROWN JV 3rd, PETERS WA, RETTENMAIER MA et al.: Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol. Oncol. (2003) 88 2):136-140.
45. HOMESLEY H, BENIGNO B, WILLIAMS J et al.: A Phase I study of weekly topotecan and Paclitaxel in previously treated epithelial ovarian carcinoma patients. Gynecol. Oncol. (2002) 87 2):171-177.
46. MORRIS RT. Weekly topotecan in the management of ovarian cancer. Gynecol. Oncol. (2003) 90(3 Pt. 2):S34-S38.
47. GORE M, OZA A, RUSTIN G et al.: A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur. J. Cancer (2002) 38(1):18-22.
48. KRUIJTZER CM, BEIJNEN JH, ROSING H et al.: Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol. (2002) 20(13):2943-2950.